

Jing Pan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5397803/publications.pdf>

Version: 2024-02-01

13
papers

711
citations

1039880

9
h-index

1199470

12
g-index

14
all docs

14
docs citations

14
times ranked

798
citing authors

#	ARTICLE	IF	CITATIONS
1	Ruxolitinib mitigates steroidâ€refractory CRS during CAR T therapy. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 1089-1099.	1.6	37
2	Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALL. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1979-1993.	2.0	15
3	Combination of <scp>CD19</scp> and <scp>CD22 CARâ€T</scp> cell therapy in relapsed Bâ€cell acute lymphoblastic leukemia after allogeneic transplantation. <i>American Journal of Hematology</i> , 2021, 96, 671-679.	2.0	62
4	A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL. <i>Blood Cancer Journal</i> , 2021, 11, 71.	2.8	17
5	Chronic restraint stress induced changes in colonic homeostasis-related indexes and tryptophan-kyurenine metabolism in rats. <i>Journal of Proteomics</i> , 2021, 240, 104190.	1.2	8
6	Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL. <i>Frontiers in Oncology</i> , 2021, 11, 640166.	1.3	12
7	Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3340-3351.	0.8	142
8	Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 23, 633-643.	1.8	5
9	Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2020, 10, 15.	2.8	101
10	Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r/r B-ALL children. <i>Leukemia</i> , 2020, 34, 3382-3387.	3.3	35
11	Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL. <i>Blood</i> , 2020, 135, 387-391.	0.6	112
12	CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia. <i>Leukemia</i> , 2019, 33, 2854-2866.	3.3	165
13	CAR T cell therapy in advanced Bâ€ALL with heavy disease burden. <i>Immunomedicine</i> , 0, , .	0.7	0